Cerevel Therapeutics Holdings Inc (FRA:673)

€ 23.6 0 (0%) Market Cap: 7.57 Bil Enterprise Value: 7.13 Bil PE Ratio: 0 PB Ratio: 14.49 GF Score: 20/100

Abbvie Inc To Acquire Cerevel Therapeutics Transcript
Dec 07, 2023
Q3 2023 Cerevel Therapeutics Holdings Inc Earnings Call Transcript
Nov 01, 2023

€22.2 (+2.78%)

Earnings
Cerevel Therapeutics Holdings Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Q2 2023 Cerevel Therapeutics Holdings Inc Earnings Call Transcript
Aug 02, 2023

€27.4

Earnings
Cerevel Therapeutics Holdings Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023
Q1 2023 Cerevel Therapeutics Holdings Inc Earnings Call Transcript
May 03, 2023

€27.6 (+8.66%)

Earnings
Cerevel Therapeutics Holdings Inc at Stifel CNS Days (Virtual) Transcript
Mar 29, 2023
Cerevel Therapeutics Holdings Inc at Cowen Health Care Conference Transcript
Mar 06, 2023
Q4 2022 Cerevel Therapeutics Holdings Inc Earnings Call Transcript
Feb 22, 2023

€23.4

Earnings
Cerevel Therapeutics Holdings Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Q3 2022 Cerevel Therapeutics Holdings Inc Earnings Call Transcript
Nov 08, 2022

Earnings
Cerevel Therapeutics Holdings Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2022
Q2 2022 Cerevel Therapeutics Holdings Inc Earnings Call Transcript
Aug 01, 2022

Earnings
Q1 2022 Cerevel Therapeutics Holdings Inc Earnings Call Transcript
May 10, 2022

Earnings
Cerevel Therapeutics Holdings Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 13, 2021
Cerevel Therapeutics Holdings Inc at Citi BioPharma Conference (Virtual) Transcript
Sep 08, 2021
Cerevel Therapeutics Holdings Inc R&D Event Transcript
Jan 28, 2021

Cerevel Therapeutics Holdings Inc R&D Event Transcript

Jan 28, 2021 / 02:00PM GMT

Transcript

Matthew Calistri;N. Anthony Coles

Cerevel Therapeutics Holdings, Inc. - VP of IR;Cerevel Therapeutics

Good morning, and welcome to Cerevel's first R&D event. Thank you for joining us. I'm Matthew Calistri, Vice President of Investor Relations. (Operator Instructions)

Before we begin, I'll make the following disclaimer. During the presentation, we will make certain forward-looking statements that reflect our current views related to our financial performance, future events and industry and market conditions as well as forward-looking statements, including the potential attributes and benefits of Cerevel's product candidates and the format and timing of Cerevel's product development activities and clinical trials. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. We strongly encourage you to review the information that Cerevel files with the SEC regarding specific risks and uncertainties.

I'll now turn it over to Tony Coles, Chairman and CEO of Cerevel Therapeutics. Thank you.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.